Skip to content

Effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and renal dysfunction

Effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and renal dysfunction

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800014308
Enrollment
Unknown
Registered
2018-01-05
Start date
2018-03-01
Completion date
Unknown
Last updated
2018-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

2: LCZ696

Sponsors

Tianjin First Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) in the diagnosis and treatment of heart failure in China guide 2014, "the diagnosis standard of CHF, and the two dimensional doppler ultrasound and ultrasound echocardiography figure, electrocardiogram, laboratory examination, biological markers such as b-type natriuretic peptide (BNP) and other auxiliary examination confirmed, the course of seven years or less; (2) the combination of light, moderate renal impairment (30 mL (1.73 m2) min/mL or less glomerular filtration rate (GFR) < 90 mL/min (1.73 m2)] [9]; (3) New York heart association (NYHA), cardiac function class for II~ III[8]. Aged 40 ~ 75 years old; Body mass index (BMI) < 30kg/m2; In the left ventricular ejection fraction (LVEF) is less than or equal to 50%; Not within 3 months prior to entry.

Exclusion criteria

Exclusion criteria: 1. renal or hepatic primary disease, hyperkalemia (blood potassium > 5.5 mmol/L), rheumatic disease, malignant tumor, Acute infection, hypotension (less than 90/60 mmHg), autoimmune disease, anemia, etc. 2. Allergic or allergic to the study; 3. complicating acute coronary syndromes (ACS), hypertrophic obstructive cardiomyopathy (HOCM), severe arrhythmia and heart diseases such as rheumatic heart valve disease (RHVD); At admission, SCr > 265 mu mol/L; The person who has a poor compliance with sex is unable to use the prescribed medicine;6. Plasma BNP < 35 ng/L.

Design outcomes

Primary

MeasureTime frame
bnp;creatinine;EF;eGFR;

Countries

China

Contacts

Public ContactLu Chengzhi

Tianjin First Central Hospital

820826393@qq.com+86 13512967656

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026